Kura Oncology, Inc. and its partner Kyowa Kirin Co., Ltd. began a Japanese Phase 2 registrational trial of ziftomenib (marketed in the United States as KOMZIFTI) for relapsed or refractory NPM1‑mutated acute myeloid leukemia (AML) on April 24 2026, when the first patient was dosed in the single‑arm, open‑label study (jRCT2031250550).
The trial targets the 30 % of AML patients worldwide who carry NPM1 mutations, a population that is also significant in Japan. By generating Japanese data, Kura and Kyowa Kirin aim to support a future regulatory filing in Japan and extend the commercial reach of KOMZIFTI beyond the United States.
Kura’s FDA approval of KOMZIFTI on November 13 2025 and the partnership with Kyowa Kirin—valued at up to $1.49 billion in capital and royalties—provide the financial and market‑access foundation for this expansion. The Japanese Phase 2 study is a key milestone in Kura’s global development strategy, positioning the company to capture a larger share of the estimated $7 billion frontline AML opportunity through combination regimens and international growth.
"Patients with R/R NPM1‑mutated AML often face limitations with existing treatment options and have a critical need for new therapeutic alternatives. Ziftomenib has the potential to provide a new treatment approach for these patients," said Yoshifumi Torii, Ph.D., Chief Medical Officer of Kyowa Kirin. "The initiation of this trial is part of Kyowa Kirin’s patient‑centered drug development efforts in our priority area of hematologic malignancies and refractory hematologic disorders." "The initiation of the Phase 2 clinical trial of ziftomenib in Japan represents a significant milestone in our global development strategy," added Mollie Leoni, M.D., Chief Medical Officer at Kura Oncology.
The launch of the Japanese trial expands KOMZIFTI’s addressable market, strengthens the partnership’s value proposition, and demonstrates Kura’s commitment to accelerating global rollout. By securing data that could lead to Japanese approval, the company positions itself to tap into a substantial patient population and potentially unlock additional revenue streams, reinforcing its strategy to grow within the AML market and beyond.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.